Pulmonary Safety of Staccato Loxapine for Inhalation in Subjects With Asthma

Trial Profile

Pulmonary Safety of Staccato Loxapine for Inhalation in Subjects With Asthma

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Loxapine (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Alexza Pharmaceuticals
  • Most Recent Events

    • 11 Oct 2010 Valeant Pharmaceuticals have announced in a media release that the US FDA have said in a Complete Response Letter that they have a clinical safety concern related to data from this study and two other phase I pulmonary safety studies.
    • 02 Sep 2009 Planned number of patients changed from 50 to 52 as reported by ClinicalTrials.gov.
    • 29 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top